Abstract:Platinum-based chemotherapeutic drugs induce intra- and interstrand crosslinks between purine residues, resulting in DNA damage and tumor cell death. Although these drugs are widely used as front-line treatment for multiple human cancers, particularly high-grade serous ovarian cancer (HGSOC), the development of platinum resistance and tumor recurrence remains a common clinical problem due to an incomplete understanding of what governs the cellular response to platinum-induced DNA damage. Here we report the results from genome-wide CRISPRi-screens for modulators of sensitivity and resistance to two widely used platinum agents, cisplatin and oxaliplatin, using a cell-based approach that mimics clinical treatment protocols. Using this unbiased genomic approach, we demonstrate that lethality after cisplatin or oxaliplatin treatment in p53-defective ovarian cancer cells is markedly enhanced by suppressing genes in the Fanconi anemia (FA) and homologous recombination (HR) pathways, but considerably less enhanced by suppressing genes in the nucleotide excision repair (NER) pathway, despite the well-established importance of NER in reversing platinum-induced intrastrand crosslinks. Loss of NER activity, however, can markedly increase tumor cell death from cisplatin-induced DNA damage, if the cell cycle checkpoint kinase MK2 is co-targeted, indicating an augmented synthetic lethal relationship between XPA, MK2, and mutant p53 in the presence of DNA crosslinks. A second targeted CRISPRi screen implicated several known and novel RNA-binding proteins (RBPs) as potent sensitizers of HGSOC to both platinum agents and taxanes, including the RNA-modifying enzyme ADAR1. Together, these findings indicate that (1) platinum-induced interstrand DNA crosslinks, which require repair by FA and HR, rather than intrastrand crosslinks repaired by NER, are the primary determinants of tumor cell survival following treatment, (2) loss of NER function alone, which only modestly sensitizes cells to platinum-induced DNA crosslinks, results in a markedly enhanced dependence of the DNA-damaged tumor cells on sustained cell cycle checkpoint arrest mediated by MK2 for tumor cell survival, and that (3) a small subset of RBPs control the sensitivity of ovarian cancer cells to both platinum-based agents and anti-microtubule drugs that form the current clinical standard of care for HGSOC. Citation Format: Yi Wen Kong, Erika D. Handly, Robin A. Lu, Molly A. Bird, Hannah-Lou Schilling, Samkyu P. Yaffe, Michael B. Yaffe, David H. Koch. Genome-wide CRISPRi screening reveals determinants of platinum sensitivity and resistance in high-grade serous ovarian cancer [abstract]. In: Proceedings of the AACR Special Conference on Ovarian Cancer; 2023 Oct 5-7; Boston, Massachusetts. Philadelphia (PA): AACR; Cancer Res 2024;84(5 Suppl_2) nr A035.

Nucleotide Excision Repair Pathway Review I: Implications in Ovarian Cancer and Platinum Sensitivity

Association of Base Excision Repair Gene Polymorphisms with the Response to Chemotherapy in Advanced Non-Small Cell Lung Cancer

Meta-analysis of excision repair cross-complementation group 1 (ERCC1) association with response to platinum- based chemotherapy in ovarian cancer.

Moving Toward Individualized Therapy Based on NER Polymorphisms That Predict Platinum Sensitivity in Ovarian Cancer Patients.

Molecular Mechanisms of Chemoresistance and Cytotoxicity Associated with Platinum Drugs

Role of Nucleotide Excision Repair in Cisplatin Resistance

DNA repair gene associated with clinical outcome of epithelial ovarian cancer treated with platinum-based chemotherapy.

Platinum Resistance in Ovarian Cancer: Role of DNA Repair

Protein Expression Levels Of Excision Repair Cross-Complementation Group 1 And Xeroderma Pigmentosum D Correlate With Response To Platinum-Based Chemotherapy In The Patients With Advanced Epithelial Ovarian Cancer

Relationship between ERCC1 (C8092A) single nucleotide polymorphism and efficacy/toxicity of platinum based chemotherapy in advanced non-small cell lung cancer patients

Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients.

Abstract A035: Genome-wide CRISPRi screening reveals determinants of platinum sensitivity and resistance in high-grade serous ovarian cancer

Molecular mechanisms of platinum‑based chemotherapy resistance in ovarian cancer (Review)

XRCC1 polymorphism and overall survival in ovarian cancer patients treated with platinum-based chemotherapy: A systematic review and MOOSE-compliant meta-analysis.

Pharmacogenomics of Platinum-Based Chemotherapy in NSCLC

Abstract 3593: Genetic Variants in NER Pathway Genes and Ovarian Cancer Risk and Outcomes

Genetic Polymorphisms and the Efficacy of Platinum-Based Chemotherapy: Review

Targeting Mre11 overcomes platinum resistance and induces synthetic lethality in XRCC1 deficient epithelial ovarian cancers

Ovarian Cancer—Insights into Platinum Resistance and Overcoming It

Reversing Platinum Resistance in High-Grade Serous Ovarian Carcinoma: Targeting BRCA and the Homologous Recombination System

Abstract B003: A multi-omic analysis to identify epigenetic drivers of platinum-resistance in high-grade serous ovarian carcinoma models